Drug – bio-affecting and body treating compositions – Nonspecific immunoeffector – per se ; or nonspecific...
Reexamination Certificate
2007-04-24
2007-04-24
Campell, Bruce R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Nonspecific immunoeffector, per se ; or nonspecific...
C530S300000, C514S002600, C514S012200, C424S085400, C424S130100
Reexamination Certificate
active
10359536
ABSTRACT:
A method and pharmaceutical combination for treating hepatitis C by administering to a hepatitis C patient an effective amount of at least one alpha thymosin peptide, in combination with administration to the hepatitis C patient of an effective amount of at least one interferon, and optionally in combination with administration of at least one antiviral agent such as ribavirin.
REFERENCES:
patent: 5762923 (1998-06-01), Gross et al.
patent: 5849696 (1998-12-01), Chretien et al.
patent: 5849800 (1998-12-01), Smith
patent: 5849860 (1998-12-01), Hakimi et al.
patent: 5869253 (1999-02-01), Draper
patent: 5908621 (1999-06-01), Glue et al.
patent: 5951974 (1999-09-01), Gilbert et al.
patent: 6001799 (1999-12-01), Chretien et al.
patent: 6172046 (2001-01-01), Albrecht
patent: 6177074 (2001-01-01), Glue et al.
patent: 6200952 (2001-03-01), Horwitz
patent: 1261806 (2000-08-01), None
patent: WO 94/13314 (1994-06-01), None
patent: WO 94/20131 (1994-09-01), None
patent: WO 99/15194 (1999-04-01), None
patent: WO 99/64016 (1999-12-01), None
patent: WO 00/37110 (2000-06-01), None
Sherman et al., Combination Therapy With Thymosin alpha 1 and Interferon. Hepatology 1998 vol. 27, pp. 1128-1135.
Weiland, Ola, Interferon and ribavirin combination therapy. Forum 2000, vol. 10, No. 1, pp. 22-28.
Rosen et al., Molecular Medicine Today, vol. 5, pp. 393-399, 1999.
Lee, William M., “Therapy of Hepatitis C: Interferon Alfa-2a Trials”,Hepatology, vol. 26, No. 3, Suppl. 1, Sep. 1997, pp. 89S-95S.
Sherman, Kenneth E. et al., “Combination Therapy with Thymosin α1 and Interferon for the Treatment of Chronic Hepatitis C Infection: A Randomized, Placebo-Controlled Double-Blind Trial”,Hepatology, vol. 27, No. 4, Apr. 1998, pp. 1128-1135.
Weiland, Ola, “Interferon and Ribavirin Combination Therapy: Indications and Schedules”,Forum, 2000, vol. 10, No. 1, 5 pages.
Kita, Y, et al., “Characterization of a polyethylene glycol conjugate of recombinant human interferon-gamma”,Drug Design and Delivery, vol. 6, No. 3, (1990), 157-167.
Sherman, K., et al. “Combination therapy with thymosin a1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial”,Hepatology, 27(4):1128-1135, 1998.
Ambrosch, A. et al., :Characteristics of the Hepatitis C virus and viral predictors of therapeutic response,Medizinische Klinik(Munich, Germany: 1983), vol. 94, No. 11, Nov. 15, 1999, pp. 626-632.
Naylor, P.H., “Zadaxin (Thymosin A1) for the Treatment of Viral Hepatitis,”Expert Opinion on Investigational Drugs, Ashley Publications Ltd., London, GB, vol. 8, No. 3, Mar. 1999, pp. 281-287.
Rosen, Hugo R. et al., “Hepatitis C virus: current understanding and prospects for future therapies,”Molecular Medicine Today, vol. 5, No. 98, Sep. 1999, pp. 393-399.
Campell Bruce R.
Hill Myron G.
Rothwell, Figg Ernst & Manbeck, PC
SciClone Pharmaceuticals Inc.
LandOfFree
Treatment of hepatitis C with thymosin and peptide... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of hepatitis C with thymosin and peptide..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of hepatitis C with thymosin and peptide... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3800632